Tregs in SLE: an Update
- 154 Downloads
Purpose of Review
There has been great interest in understanding why T regulatory cells (Tregs) are reduced in number and/or in function in several autoimmune diseases including systemic lupus erythematosus (SLE). Although research has provided some answers, there is still much to learn.
Recent investigations on the mechanisms responsible for the impairment of the Tregs in SLE have identified relevant abnormalities in cellular and molecular pathways that have been instrumental in the design of studies in animal models and in the development of pilot immunotherapeutic studies in lupus patients.
We review the progress made in the field in the last 5 years, discussing the mechanistic studies, together with the preclinical and clinical works that are moving forward the understanding of the physiopathology of Tregs in SLE.
KeywordsSLE T regulatory cells
Compliance with Ethical Standards
Conflict of Interest
The author declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 9.Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723–35. https://doi.org/10.1084/jem.20041982.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108(5):1571–9. https://doi.org/10.1182/blood-2006-02-004747.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Comte D, Karampetsou MP, Kis-Toth K, Yoshida N, Bradley SJ, Mizui M, et al. Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2016;113(33):9321–6. https://doi.org/10.1073/pnas.1605081113.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-β dependent but does not confer a regulatory phenotype. Blood. 2007;110(8):2983–90. https://doi.org/10.1182/blood-2007-06-094656.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol. 2006;177(3):1451–9. https://doi.org/10.4049/jimmunol.177.3.1451.CrossRefPubMedGoogle Scholar
- 20.Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010;184(7):3433–41. https://doi.org/10.4049/jimmunol.0904028.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Miyara M, Chader D, Sage E, Sugiyama D, Nishikawa H, Bouvry D, et al. Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc Natl Acad Sci U S A. 2015;112(23):7225–30. https://doi.org/10.1073/pnas.1508224112.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Wong M, La Cava A, Hahn BH. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol. 2013;190(11):5402–10. https://doi.org/10.4049/jimmunol.1202382.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.•• Apostolidis SA, Rodríguez-Rodríguez N, Suárez-Fueyo A, Dioufa N, Ozcan E, Crispín JC, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17(5):556–64. This study revealed the importance of the serine-threonine phosphatase PP2A in the function of Tregs and in the prevention of autoimmunity. Tregs were found to have high PP2A activity, and the ablation of the PP2A complex in Tregs led to development of severe autoimmune manifestations. https://doi.org/10.1038/ni.3390.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Sharabi A, Kasper IR, Tsokos GC. The serine/threonine protein phosphatase 2A controls autoimmunity. Clin Immunol. 2018.Google Scholar
- 41.Yu Y, Liu Y, Shi FD, Zou H, Hahn BH, La Cava A. Tolerance induced by anti-DNA Ig peptide in (NZB × NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. Clin Immunol. 2012;142(3):291–5. https://doi.org/10.1016/j.clim.2011.11.004.CrossRefPubMedGoogle Scholar
- 45.• Pan W, Zhu S, Dai D, Liu Z, Li D, Li B, et al. MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Nat Commun. 2015;6:7096. This study identified miR-125a as a critical factor in the stabilization of Tregs and the control of autoimmune disease. https://doi.org/10.1038/ncomms8096.CrossRefPubMedGoogle Scholar
- 48.• von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407–15. This study showed that treatment of a small number of SLE patients with a low-dose IL-2 regimen expanded functional Tregs in vivo . https://doi.org/10.1136/annrheumdis-2015-207776.CrossRefGoogle Scholar
- 49.• He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–3. This study showed that treatment of 38 lupus patients with low-dose IL-2 resulted in the reductions of disease activity in all patients. The findings associated with increased Tregs frequency and reduced Tfh and Th17 cell responses. However, the results were not conclusive due to limitations in the study including the recruitment of the control group after end of treatment in the experimental group. https://doi.org/10.1038/nm.4148.CrossRefPubMedGoogle Scholar
- 50.Lai ZW, Hanczko R, Bonilla E, Caza TN, Clair B, Bartos A, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2012;64(9):2937–46. https://doi.org/10.1002/art.34502.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Lai ZW, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R, et al. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol. 2013;191(5):2236–46. https://doi.org/10.4049/jimmunol.1301005.CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Qiao G, Yang L, Li Z, Williams JW, Zhang J. A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells. Clin Immunol. 2015;157(2):166–74. https://doi.org/10.1016/j.clim.2015.01.006.CrossRefPubMedGoogle Scholar
- 56.Koga T, Mizui M, Yoshida N, Otomo K, Lieberman LA, Crispín JC, et al. KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3+ regulatory T cells in MRL/lpr mice. Autoimmunity. 2014;47(7):445–50. https://doi.org/10.3109/08916934.2014.915954.CrossRefPubMedPubMedCentralGoogle Scholar
- 57.Zhang L, Bertucci AM, Ramsey-Goldman R, Harsha-Strong ER, Burt RK, Datta SK. Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity. Clin Immunol. 2013;149(3):365–78. https://doi.org/10.1016/j.clim.2013.08.008.CrossRefPubMedGoogle Scholar